Skip Ribbon Commands
Skip to main content
Sign In

26324 Haemophilus influenzae Type B Antibody, IgG, Serum (HIBSG)

Haemophilus influenzae Type B Antibody, IgG, Serum (HIBSG)
Test Code: MISC
Synonyms/Keywords

​H. influenzae Antibody
Haemophilus influenzae B Vaccine Response
HIB (Haemophilus influenzae Type B) Vaccine Response

Useful For

​Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine

Assessing immunity against HIB

Aiding in the evaluation of immunodeficiency when the patient is tested pre- and post-vaccination

Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum​Serum Separator Tube (SST)​Red Top Tube (RTT)​0.5 mL​0.4 mL
Specimen Stability Information
Specimen TypeTemperatureTime
​Serum ​​Refrigerated (preferred)​7 Days
​Frozen​7 Days
Rejection Criteria

​Gross Hemolysis
​Gross Lipemia
​Heat-Inactivated

 

Interference

​This assay does not provide diagnostic proof of the presence or absence of immune deficiency. Results must be confirmed by clinical findings and other laboratory tests.

Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
​Mayo Clinic Laboratories​Monday, Wednesday, Friday​1-6 Days​Enzyme Immunoassay (EIA)
Reference Lab
Test Information

Haemophilus influenzae type B (HIB) is an encapsulated Gram-negative cocco-bacillary bacterium that can cause devastating disease in unvaccinated young children, including meningitis, bacteremia, cellulitis, epiglottitis, pneumonia, and septic arthritis. The outer surface of H influenzae is covered by a polyribosyl-ribitol-phosphate (PRP) polysaccharide that is responsible for both pathogenicity and immunity. There are currently 6 recognized PRP serotypes, referred to as a through f, among which serotype b, prior to the availability of a vaccine, accounted for up to 95% of infections. There are also unencapsulated or nontypable strains.

Prior infection with H influenzae is associated with protective immunity against reinfection. One of the great advances in modern medicine has been the development of an effective vaccine against HIB, which is based on use of an unconjugated, purified PRP antigen. A patient's immunological response to HIB vaccine can be determined by measuring anti-HIB IgG antibody levels using a standardized enzyme immunoassay (EIA). Antibody levels of1 mcg/mL or more at least 3 weeks after vaccination has been correlated with long-term protective immunity.

Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories

​> or =0.15 mg/L

Reference values apply to all ages.

Interpretation

​An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15 mcg/L is generally accepted as the minimum level for protection at a given time; however, it does not confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0 mcg/L postimmunization. Furthermore, studies have shown that the response to HIB vaccine is age-related.

Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
​87385​1
Synonyms/Keywords

​H. influenzae Antibody
Haemophilus influenzae B Vaccine Response
HIB (Haemophilus influenzae Type B) Vaccine Response

Ordering Applications
Ordering ApplicationDescription
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum​Serum Separator Tube (SST)​Red Top Tube (RTT)​0.5 mL​0.4 mL
Specimen Stability Information
Specimen TypeTemperatureTime
​Serum ​​Refrigerated (preferred)​7 Days
​Frozen​7 Days
Rejection Criteria

​Gross Hemolysis
​Gross Lipemia
​Heat-Inactivated

 

Interference

​This assay does not provide diagnostic proof of the presence or absence of immune deficiency. Results must be confirmed by clinical findings and other laboratory tests.

Useful For

​Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine

Assessing immunity against HIB

Aiding in the evaluation of immunodeficiency when the patient is tested pre- and post-vaccination

Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories

​> or =0.15 mg/L

Reference values apply to all ages.

Interpretation

​An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15 mcg/L is generally accepted as the minimum level for protection at a given time; however, it does not confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0 mcg/L postimmunization. Furthermore, studies have shown that the response to HIB vaccine is age-related.

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
​Mayo Clinic Laboratories​Monday, Wednesday, Friday​1-6 Days​Enzyme Immunoassay (EIA)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
​87385​1
For most current information refer to the Marshfield Laboratory online reference manual.